Logo of chimantherBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleChiropractic & Manual TherapiesJournal Front Page
PMC full text:
Copyright/License ►Request permission to reuse

Table 4

Data collection schedule

 BEV1BEV2W4W12W24W36W37W52W78
Demographics
X
 
 
 
 
 
 
 
 
Clinical characteristics/physical examination
X
 
 
 
 
 
 
 
 
Self-report outcome measures
 Disability: NDI [[49]] and ODI [[50]]
X
X
X
X
X
X
 
X
X
 Pain: 11-box scale [[51]]
X
X
X
X
X
X
 
X
X
 General health: EuroQol EQ-5D [[52]]
X
X
X
X
X
X
 
X
X
 Improvement [[40],[53],[54]]
 
 
X
X
X
X
 
X
X
 Pain Self-Efficacy Questionnaire [[55]]
X
X
X
X
X
X
 
X
X
 Tampa Scale for Kinesiophobia [[56],[57]]
X
X
X
X
X
X
 
X
X
 Satisfaction [[40],[53],[54]]
 
 
X
X
X
X
 
X
X
 Medication use [[40],[53]]
X
X
X
X
X
X
 
X
X
 Expectations [[40],[53]]
 
X
 
X
X
X
 
X
 
 Falls [[58]]
 
X
 
X
X
X
 
X
X
 *Side effects [[40],[59]]
 
 
X
X
X
X
 
 
 
 Home exercise frequency
 
 
X
X
X
X
 
X
X
 Self-reported influence
X
X
X
X
X
X
 
X
X
Functional outcome measures
 Hand grip strength [[60]]
 
X
 
 
 
 
X
 
 
 Short physical performance battery (SPPB) [[61],[62]]
 
X
 
 
 
 
X
 
 
 Accelerometry (7 days) [[63]]
 
X
 
 
 
X
 
 
 
Qualitative data collection
 Interviews   X 12wk X 36wk   
BEV = Baseline evaluation; W = weeks post-randomization; 12wk = 12 week treatment group only; 36wk = 36 week treatment group only.

*Also collected at treatment visits during intervention phase: BL2-W12 for 12wk group; BL2-W36 for 36wk group.